A clinical trial that was a big part of a more than $1 billion partnership between a large drugmaker and a small-cap biotech company has flopped. The partnership between the two companies had been ...

Bristol-Myers Squibb's $14 billion bet on buying Karuna Therapeutics looks set to pay off after it got FDA approval for the schizophrenia drug at the heart of the deal. The US regulator has cleared ...

The ink is dry and the keys to a former Bristol Myers Squibb production facility in East Syracuse, New York, have been handed over to Lotte Biologics. The handover was completed Jan. 1, putting a cap ...

Bristol Myers Squibb seems to have found a friend in Avidity Biosciences, as the two add a second link to a heart-focused research partnership for $100 million upfront. The two companies tied the ...

The litany of big-ticket deals involving antibody-drug conjugates shows no sign of ending. In the latest recitation, Bristol-Myers Squibb is paying $800 million upfront for rights to a HER3-directed ...

Bristol Myers Squibb’s recently acquired schizophrenia drug demonstrated persistent symptom improvement without patients gaining weight, according to new long-term data, bolstering excitement around ...